NSE · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at -0.95 against a street estimate of -3.00 — a beat of 68.3%.
with an average price target of ₹264.00.
MIXED Q1 FY27 revenue grew 5.8% standalone, 8.2% consolidated. EBITDA margins expanded YoY but compressed QoQ. U.S. surged 62%, Europe flat, emerging markets declined. Waiting on critical FDA audit for sterile plant. Q1 FY27 U.S. growth masks sterile audit stall; Europe hindered by shipping timing, not demand; emerging markets expected temporary only. Analysts pressed FDA timing (no date), international market softness (cited timing/war, not demand), debt trajectory (INR 260cr near-term target). Management defended Q1 dips as temporary seasonal/logistical, reaffirmed long-term growth thesis conditional on audit clearance. 2026-07-28…
Full summary in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Indoco Remedies Limited — free to start.
Google PlayApp StoreData updated 2026-08-05.